Members of the Food and Drug Administration’s vaccine expert panel on Thursday endorsed boosters for Moderna recipients who are at high risk of severe COVID-19, occupational exposure to COVID-19 or are 65 years and older.
The unanimous decision mirrors the FDA conditions for those who qualify for a Pfizer booster.Subscribe for freeDespite small data sample sizes and limited data, the agency noted several times it would need a strong justification to say no to Moderna boosters when it already approved these conditions for Pfizer.
Antibody levels dropped six to eight months after vaccination, however, according to Miller. A half-dose booster at least six months after initial vaccination restored those antibodies in a study of nearly 300 people.Moderna has been in the hot seat this past week over its distribution of vaccine doses globally.
The presented data from Israel indicated boosters for Pfizer reduced the rate of severe disease by 60-80%. The number of severe cases in people under 40, however, was too small to conclude.Until this point, the agency has only voted on boosters for Americans who received the Pfizer vaccine, leaving Moderna and Johnson & Johnson recipients with little guidance as data trickle in.
New data from the National Institutes of Health show people who got the Johnson & Johnson vaccine might benefit from getting a Pfizer or Moderna booster shot. But J&J has asked the FDA to approve a second shot for its own vaccine.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Staff Don’t Take Position on Moderna Covid-19 BoosterIn an unusual move, FDA staff didn't take a position on Moderna's application for a booster shot, indicating there may be insufficient data to support one
Read more »
FDA to take up Moderna, J&J Covid-19 booster questions this weekVaccine advisers to the FDA meet Thursday and Friday of this week to tackle the next round of questions about booster vaccines for Covid-19 — and they might be seeing the first trickle of data on mix-and-match boosters.
Read more »
COVID-19 Live Updates: FDA to hold crunch talks over J&J and Moderna vaccine boostersThe Food and Drug Administration is set to hold crucial meetings over the next two days to decide whether to issue booster shots of Johnson & Johnson and Moderna COVID vaccines. Follow Newsweek's liveblog for all the latest.
Read more »
Moderna has no plans to share its COVID-19 vaccine recipe, aims to increase production insteadModerna won't share the recipe for its COVID-19 vaccine because execs have concluded that scaling up the company’s own production is the best way to increase the global supply, the company’s chairman said.
Read more »
J&J Covid-19 Vaccine Recipients May Benefit More From Pfizer Or Moderna Boosters, Study FindsJ&J recipients who were administered Moderna or Pfizer boosters showed significantly higher antibody counts compared to those who received a booster of the same vaccine.
Read more »
White House's chief Covid-19 science officer calls on Moderna to 'step up' global vaccine effortsThe White House's top scientist focused on Covid-19 sought to ratchet up pressure on Moderna, saying the pharmaceutical giant needs to 'step up' to provide more of its Covid-19 vaccine to the world in the urgent race to get the pandemic under control.
Read more »